First China Biotech IPO in Two Years Lands in U.S.

(Bloomberg) -- I-Mab Biopharma Co., a Chinese drug developer, has launched what is set to be the first U.S. initial public offering by a Chinese biotech company in more than two years.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.